Susquehanna International Group
TAK icon

Susquehanna International Group’s Takeda Pharmaceutical TAK Stock Holding History

Susquehanna International Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,800
Closed -$213K – 13840
2025
Q2 		$213K Sell
13,800
-7,300
-35% -$108K ﹤0.01% 11081
2025
Q1 		$314K Buy
21,100
+5,100
+32% +$71.5K ﹤0.01% 9977
2024
Q4 		$212K Buy
+16,000
New +$220K ﹤0.01% 10614
2023
Q4 		– Sell
-12,200
Closed -$189K – 13272
2023
Q3 		$189K Sell
12,200
-1,200
-9% -$18.6K ﹤0.01% 10293
2023
Q2 		$211K Sell
13,400
-300
-2% -$4.92K ﹤0.01% 10167
2023
Q1 		$226K Sell
13,700
-37,900
-73% -$604K ﹤0.01% 10336
2022
Q4 		$805K Buy
51,600
+2,100
+4% +$29.3K ﹤0.01% 6658
2022
Q3 		$642K Sell
49,500
-85,600
-63% -$1.19M ﹤0.01% 7791
2022
Q2 		$1.9M Sell
135,100
-1,900
-1% -$27.1K ﹤0.01% 5019
2022
Q1 		$1.96M Sell
137,000
-97,700
-42% -$1.43M ﹤0.01% 5525
2021
Q4 		$3.2M Sell
234,700
-596,300
-72% -$8.36M ﹤0.01% 4528
2021
Q3 		$13.6M Sell
831,000
-135,600
-14% -$2.28M ﹤0.01% 2458
2021
Q2 		$16.3M Sell
966,600
-1,245,800
-56% -$21.2M ﹤0.01% 2283
2021
Q1 		$40.4M Buy
2,212,400
+1,501,400
+211% +$27M 0.01% 1263
2020
Q4 		$12.9M Buy
711,000
+86,300
+14% +$1.51M ﹤0.01% 2195
2020
Q3 		$11.1M Sell
624,700
-32,400
-5% -$590K ﹤0.01% 2054
2020
Q2 		$11.8M Sell
657,100
-28,800
-4% -$517K ﹤0.01% 1949
2020
Q1 		$10.4M Sell
685,900
-229,900
-25% -$4.17M ﹤0.01% 1696
2019
Q4 		$18.1M Sell
915,800
-43,800
-5% -$838K 0.01% 1514
2019
Q3 		$16.5M Buy
959,600
+71,800
+8% +$1.24M 0.01% 1491
2019
Q2 		$15.7M Sell
887,800
-17,200
-2% -$313K 0.01% 1477
2019
Q1 		$18.4M Buy
905,000
+876,000
+3,021% +$17.6M 0.01% 1259
2018
Q4 		$488K Buy
+29,000
New +$490K ﹤0.01% 6084

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group's TAK Position: Q1 2026 in Review

Susquehanna International Group increased its Takeda Pharmaceutical (TAK) stake by 44% in Q1 2026, buying an estimated $224K and bringing the position to 41,424 shares worth $767K. The position accounts for ﹤0.01% of the portfolio, ranked #8581.

Susquehanna International Group first reported a position in TAK in Q2 2019 and has held it in 25 quarters since. The position peaked at $28.1M in Q1 2021. 359 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • Susquehanna International Group held 41,424 shares of Takeda Pharmaceutical worth $767K as of Q1 2026.
  • Susquehanna International Group bought 12,749 Takeda Pharmaceutical shares in Q1 2026, an estimated $224K.
  • Takeda Pharmaceutical made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8581 holding.
  • Susquehanna International Group first reported a position in Takeda Pharmaceutical in Q2 2019 and has held it in 25 quarters since.
  • Susquehanna International Group's Takeda Pharmaceutical position peaked at $28.1M in Q1 2021.
  • 359 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.